Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyun Ju | - |
dc.contributor.author | Chang, Jee Suk | - |
dc.contributor.author | Roh, Mi Ryung | - |
dc.contributor.author | Oh, Byung Ho | - |
dc.contributor.author | Chung, Kee-Yang | - |
dc.contributor.author | Shin, Sang Joon | - |
dc.contributor.author | Koom, Woong Sub | - |
dc.date.available | 2020-02-27T02:40:41Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-09-04 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1140 | - |
dc.description.abstract | Objective: Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy of radiotherapy (RT), especially combined with immune checkpoint inhibitors (ICIs), for this rare melanoma subtype remains unknown. We investigated the reciprocal effect of RT and ICI on mucosal melanoma patients. Materials and Methods: We identified 23 patients with 31 tumors who were treated with RT between July 2008 and February 2017. All patients received RT for primary or metastatic gross tumor mass with a median dose of 4 Gy per fraction (range 1.8-12 Gy). Eleven patients (14 lesions) were treated with RT alone, whereas 12 (17 lesions) were administered pembrolizumab combined with RT (ICI+RT group). The local control (LC) and adverse event (AE) rates were compared between the groups. Eight patients with metastatic mucosal melanoma treated with ICI alone during the same study period were included as a comparison group. Results: The median follow-up period was 17.4 (range 3.7-95.2) months. The target lesion control rate at 1-year was significantly higher in the ICI+RT group than in the RT-alone group or ICI-alone group (94.1% vs. 57.1% vs. 25%; P < 0.05). No abscopal effect was observed in our cohort. Treatment-related AEs were not significantly increased in the combined treatment group compared with the RT-alone group (P > 0.05). No grade >= 3 AEs occurred in the ICI+RT group. Conclusions: Besides RT acting as an immune adjuvant, ICI might have a radiosensitizing effect and may increase LC without severe toxicity. We have initiated a phase II study to determine the effects of RT in patients with melanoma undergoing anti-PD1 (NCT04017897). | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
dc.subject | RADIATION-THERAPY | - |
dc.subject | POSTOPERATIVE RADIOTHERAPY | - |
dc.subject | NONCUTANEOUS MELANOMA | - |
dc.subject | CHOICE CHEMOTHERAPY | - |
dc.subject | MALIGNANT-MELANOMA | - |
dc.subject | CHECKMATE 037 | - |
dc.subject | OPEN-LABEL | - |
dc.subject | SURVIVAL | - |
dc.subject | HEAD | - |
dc.subject | IMMUNOTHERAPY | - |
dc.title | Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000483735000001 | - |
dc.identifier.doi | 10.3389/fonc.2019.00835 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, v.9 | - |
dc.identifier.scopusid | 2-s2.0-85072957718 | - |
dc.citation.title | FRONTIERS IN ONCOLOGY | - |
dc.citation.volume | 9 | - |
dc.contributor.affiliatedAuthor | Kim, Hyun Ju | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | melanoma | - |
dc.subject.keywordAuthor | immunotherapy | - |
dc.subject.keywordAuthor | radiotherapy | - |
dc.subject.keywordAuthor | local control | - |
dc.subject.keywordAuthor | adverse events | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | POSTOPERATIVE RADIOTHERAPY | - |
dc.subject.keywordPlus | NONCUTANEOUS MELANOMA | - |
dc.subject.keywordPlus | CHOICE CHEMOTHERAPY | - |
dc.subject.keywordPlus | MALIGNANT-MELANOMA | - |
dc.subject.keywordPlus | CHECKMATE 037 | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | HEAD | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.